Outcome Health: The Digital Health Advertising Company the DOJ and SEC Say Billed Pharma Clients for Screens That Did Not Exist

Outcome Health LLC, a Chicago-based health technology company that sold digital advertising space on screens placed in physician waiting rooms and exam rooms, faced Department of Justice criminal charges and Securities and Exchange Commission civil charges against its founders and executives after federal investigators concluded the company had systematically billed pharmaceutical advertising clients for placements on screens that had never been installed and for audience metrics it had fabricated or inflated.DOCUMENTED

The scheme, as described in federal charging documents, operated across multiple dimensions: Outcome Health told pharmaceutical clients it had a larger network of installed screens than it actually did, charged for advertising campaigns run on devices that did not exist or were not functional, misrepresented the viewership data it provided to clients as independent verification, and then raised hundreds of millions of dollars in investment capital from major institutions on financial metrics that incorporated revenue from these fraudulent billings.

The Point-of-Care Advertising Model and Its Exploitation

Point-of-care advertising — placing branded content in clinical settings where patients are waiting or receiving care — is a legitimate and substantial pharmaceutical marketing channel. Physicians' offices, clinics, and hospital waiting areas are locations where patients are already primed to think about health conditions and treatments, making them valuable environments for drug manufacturers to reach patients immediately before or after conversations with their doctors. Outcome Health built its business on this premise, offering pharmaceutical clients the ability to place digital content on screens deployed across a network of clinical partners.REVIEWED

The company's alleged fraud exploited a fundamental information asymmetry in the advertising verification process: pharmaceutical clients purchasing screen-based advertising could not easily verify that the screens they were paying for were actually installed and functioning at the claimed locations. Unlike digital advertising on the open web — where third-party measurement companies can track impressions and verify delivery with reasonable precision — physical screen advertising in clinical settings requires either in-person audits or trust in the seller's self-reported metrics. Outcome Health's executives allegedly understood this limitation and used it to bill clients for inventory that did not exist.DOCUMENTED

How the Billing Inflation Operated

Federal charging documents described a system in which Outcome Health's sales and operations teams maintained inflated network counts when presenting to pharmaceutical clients — representing that screens were installed and operational at clinic locations where the company had agreements but had not yet completed installation, or at locations where screens had been removed. Billing for advertising campaigns was calculated based on the inflated network count rather than the actual installed base, meaning clients paid for impressions that could not have been delivered because the displays were not present.REVIEWED

Internal communications cited in the charging documents showed that employees raised concerns about the gap between sold inventory and actual installed inventory, and that executives directed staff to continue billing at the higher rate while the installation backlog was addressed. When clients asked for verification of the screen network, the company provided representations that the DOJ alleged were false. Third-party audit results that showed lower screen counts than the company claimed were, according to the charges, suppressed rather than disclosed to clients.

Selling advertising on screens that do not exist is not a delivery shortfall. It is fraud — and the audit results that would have revealed it were buried rather than disclosed.

The Investor Fundraising Dimension

The securities fraud dimension of the case arose from Outcome Health's capital raising activities. The company raised approximately $487 million in debt and equity financing from institutional investors — including Goldman Sachs, Pritzker Group, and other sophisticated financial institutions — presenting financial metrics that incorporated revenue from the fraudulently billed advertising contracts. Investors who evaluated Outcome Health based on these revenue figures were making decisions on the basis of financial performance that the DOJ and SEC alleged was substantially falsified.DOCUMENTED

The company's implied valuation exceeded $5 billion at the peak of its fundraising, a figure that reflected investor confidence in a business model premised on a screen network and revenue base that investigators later concluded were materially misrepresented. When the fraud was exposed, the company's actual enterprise value was a fraction of the valuation at which investors had committed capital, creating losses across the institutional investor base that had funded the company's growth.

Charges and Individual Accountability

The DOJ's charges were directed at Outcome Health's founders and multiple senior executives, including the CEO, president, and chief revenue officer. The criminal charges included wire fraud, bank fraud, and securities fraud — offenses carrying potential sentences of up to 20 to 30 years per count. The SEC's parallel civil action sought disgorgement of gains and civil monetary penalties from the individual executives and the company. The structure of the charges — targeting the individuals who directed the scheme rather than the corporate entity alone — reflected the DOJ's stated priority of holding executives personally accountable for corporate fraud rather than allowing institutional settlements to effectively shield responsible individuals.DOCUMENTED

The pharmaceutical companies that had been defrauded were positioned as victims in the criminal case, and some pursued civil recoveries through direct litigation against the company and its executives. The overlap between the criminal victims — the pharma clients — and the civil investor victims created a complex restitution and recovery environment in which multiple parties with different legal interests were attempting to recover from a company whose actual assets were far smaller than the value of the claims against it.

Verification Lessons for Advertising Clients

The Outcome Health case has practical implications for any advertiser purchasing inventory in a physical media channel where independent verification is not built into the transaction. Digital advertising buyers routinely use independent third-party measurement vendors to verify impression delivery — a practice that has become standard precisely because self-reported metrics from sellers are not always reliable. Physical advertising channels, including point-of-care screens, out-of-home displays, and in-store placements, present greater verification challenges, but those challenges do not make independent verification impossible. Advertisers with significant spend in these channels can and should build independent audit requirements into their contracts, including the right to conduct unannounced physical verification of claimed inventory.REVIEWED

Have documents relevant to this story? Reach us through our tips channel.